1. Introduction -- the need for new antiparasitic drugs {#s0005}
=======================================================

The prevalence and persistence of parasitic infections are both remarkable and troubling phenomena. Approximately one billion people harbour at least one worm infection (nematodes and platyhelminths) ([@b0340]) and many individuals are simultaneously infected with multiple parasites from distantly related eukaryotic phyla ([@b0125; @b0150; @b0355]). These parasites cause diseases that impose a serious burden to the health and economic development of affected countries, and are therefore the subject of many varied prevention and control strategies. No human-licensed vaccine exists for any eukaryotic disease, therefore drugs are a major component of intervention against most parasitic diseases ([@b0390]). Drug based strategies include treatment of verified infections, mass drug administration to presumptive infected communities or at risk individuals (e.g. pregnant mothers), and sporadic prophylaxis for individuals. In many cases existing drug-based programs are at risk from parasites developing resistance, and therefore rendering ineffective our affordable and effective drugs. Some antiparasitic drugs have already had their effective usage severely restricted in regions due to the development of widespread drug resistance ([@b0030; @b0095]). The development of future control strategies is threatened by the impending and inevitable emergence of resistance to additional drugs ([@b0145]). To deal with existing and future shortcomings of antiparasitic drugs, multiple classes of new drugs are urgently needed for many parasitic diseases.

Parasites cause diverse types of disease, requiring drug treatments that address varying causes of pathogenesis. Apicomplexan parasites include *Plasmodium* spp., *Toxoplasma gondii* and *Cryptosporidium*. All parasites in this phylum are obligate intracellular parasites, but their host range and disease type varies immensely. *Plasmodium* species cause generally acute disease through proliferation within and destruction of erythrocytes. Most existing anti-malarial drugs work by killing this proliferative intra-erythrocytic stage, though action against the parasite forms that initially infect humans (sporozoites) and the forms that are transmitted to mosquitoes (gametocytes) is highly desirable in addition to disease control purposes ([@b0580]). *Toxoplasma gondii* parasites infect many diverse animals and many cell types. In humans, *Toxoplasma* is normally pathogenic only in immunocompromised individuals or in the human foetus. Drugs are needed to arrest the faster growing tachyzoite stages of *Toxoplasma*, as well as the latent bradyzoite stages that form cysts in the brain and other organs ([@b0585]). *Cryptosporidium* infects epithelial cells of the intestine, causing potentially severe and chronic diarrhea. As with *Toxoplasma*, the most severe *Cryptosporidium* cases are in immunocompromised individuals, and the need for drugs is more pressing for treatment of such cases ([@b0420]).

Typanosomatid parasites also cause a broad spectrum of diseases. *Trypanosoma brucei*, spread by the bite of the tsetse fly, causes human African trypanosomiasis, also known as sleeping sickness. These parasites proliferate extra-cellularly in the bloodstream and lymphatic system and later infect the central nervous system (CNS) ([@b0575]). This disease is fatal within months to years if not treated, and most existing treatments are difficult to administer, toxic or ineffective. New drugs must overcome the additional challenge of crossing the blood brain barrier to treat parasites in the CNS. *Trypanosoma cruzi* infections are the cause of the chronic and potentially fatal Chagas disease. Existing drugs to treat *T. cruzi* are ineffective if not administered early during infection and are highly toxic. *Leishmania*, the second medically important genus of trypanosomatid parasites, includes species that also cause a range of serious human diseases. In humans, *Leishmania* parasites invade and grow within phagocytic cells. As with other trypanosomatid parasites, existing drugs are generally toxic, difficult to deliver and subject to parasite resistance ([@b0475]). Although trypanosomatid parasites kill fewer people than malaria, the lack of effective and safe drugs arguably makes discovery of new drugs even more pressing for these parasites.

Three parasites whose anaerobic metabolism distinguishes them from most other eukaryotes are the extracellular parasites *Giardia*, *Trichomonas*, and *Entamoeba.* In these parasites the mainstays for treatment are the nitroimidazole drugs, which are activated by the parasites' unusual pyruvate:ferredoxin oxidoreductase enzymes ([@b0570]). In each of these parasites, resistance to nitroimidazol is possible through altered metabolism and alternative drugs are scarce or ineffective ([@b0500]).

The final parasite discussed below in the context of tRNA synthetase targets is the helminth parasite *Brugia*. *Brugia malayi* is a nematode spread between humans by mosquitoes and is one of several parasites to cause human filariasis. Lymphatic filariasis is caused by immunological reaction to the adult worms and the thousands of transmissive microfilaria they produce. Drug discovery against nematodes introduces the added difficulty of selective inhibition between the bilaterian animal parasites and their hosts, although *Brugia*'s dependence on its bacterial *Wolbachia* symbiont may offer other potential drug targets ([@b0035]).

2. Protein translation as a drug target {#s0010}
=======================================

One biological pathway that has been thoroughly validated as a target for anti-infective compounds in a wide range of microbes is the process of protein translation. Most antibiotics that target protein translation interact with microbial ribosomes themselves---binding directly to the rRNA or ribosomal subunit proteins. However, additional molecules within the broader process of protein translation can act as targets for drugs. One such target for existing and future antimicrobial therapeutics is the aminoacyl-tRNA synthetase (aaRS) family. This family of enzymes catalyses the attachment of amino acids to their cognate tRNAs to produce the aminoacyl tRNAs (also aa-tRNA or charged tRNA) that are the substrates for translation (reviewed by [@b0195]). The aaRSs enzymes are not only responsible for producing the raw materials for translation, but also for ensuring the fidelity of translation from nucleic acid to amino acid information. Disruption of aaRSs therefore interrupts or poisons the process of protein translation. Compounds that inhibit aaRSs have been successfully exploited, with at least one antibacterial drug, mupirocin, currently in clinical use for the topical treatment of *Staphylococcus aureus*, that acts through the inhibition of the isoleucyl-tRNA synthetase (IleRS) of gram-positive bacteria ([@b0360]). The pursuit of diverse other aminoacyl-tRNA synthetases has yielded specific aaRS inhibitors ([@b0415]), some of which are currently in clinical trials as antimicrobials ([@b0105; @b0285]).

Besides the excellent precedence for druggability in bacteria, there are several reasons to support protein translation in general, and aaRSs specifically, as a useful antiparasitic target. First is the dependence of many parasites on abundant protein translation in fast growing cells. Because many parasites constitutively undergo active and continuous proliferation they are heavily reliant on efficient protein translation and may be sensitive to disruptions to the translation machinery. Other parasites pass through quiescent life-stages with relatively little cellular proliferation---these stages (such as the bradyzoite stages of *Toxoplasma gondii*) are likely to have a reduced requirement for protein turnover and may be less sensitive to translation inhibitors. Such stages present a general problem for chemotherapy, though it is noteworthy that inhibition of housekeeping functions, such as the block of gene expression by rifampicin, has been successfully exploited for slow-growing microbes such as latent stage *Mycobacterium tuberculosis* ([@b0330]). A second aspect of parasite protein translation that renders it a plausible drug target is the immense evolutionary distance between this process in some parasites and human hosts. Furthermore, several parasites have bacterial-like protein translation pathways that are not shared by humans. Apicomplexan parasites in particular, are dependent on their relict plastid (apicoplast), which retains much of the cyanobacterial protein translation apparatus of plastids' ancestor ([@b0210]). Trypanosomatid parasites are highly dependent on protein translation in their unusual kinetoplastid mitochondrion, and the protein translation therein differs in several aspects from the translation found in human mitochondria or cytosol ([@b0435; @b0370]). These examples highlight the presence of aaRSs in multiple organelles, all of which may be considered when contemplating drug targets.

A number of recent reviews have detailed drug discovery and development against bacterial and fungal aaRSs ([@b0265; @b0375; @b0505; @b0345]). In this review we discuss prospects for drug development against the aaRSs of eukaryotic parasites, including apicomplexan, trypanosomatid, and metamonad protists as well as parasitic worms.

3. Aminoacyl-tRNA synthetases as drug targets {#s0015}
=============================================

Before considering specific parasite targets, let us briefly consider what types of activities might be inhibited when focusing on aaRSs. Aminoacyl-tRNA synthetases catalyse a two-step reaction whereby an ATP and amino acid molecule (AA) enter the active site, forming an aminoacyl-adenylate intermediate (1), followed by the esterification of the amino acid to the 3′ end of the tRNA, forming the final 'charged' aminoacyl-tRNA (2).$$\left. \text{AA} + \text{ATP} + \text{AARS}\ \leftrightharpoons\ \text{AARS} \cdot \text{AA-AMP} + \text{PPi} \right.$$$$\left. \text{AARS} \cdot \text{AA-AMP} + \text{tRNA}\ \leftrightharpoons\ \text{AARS} + \text{AA-tRNA} + \text{AMP} \right.$$

This presents several sites on aaRS enzymes that may be considered for drugging purposes; a binding site for ATP, an adjacent amino acid binding site, and a fold for tRNA recognition and binding ([Fig. 1](#f0005){ref-type="fig"}). Most aaRS inhibitors bind to the ATP and amino acid binding sites, in many cases as analogues of ATP, amino acids, or aminoacyl-adenylate intermediates ([@b0505]). Below we review prospects for antiparasitic drug development from such inhibitors for each of the tRNA synthetases.

Discrimination between different amino acids with similar chemical structures is a biochemical challenge and some aminoacyl-tRNA synthetases are prone to errors in charging. Errors can be reduced by recognition and elimination of misactivated noncognate amino acids, or through editing of misacylated tRNAs. Proof-reading is achieved both through editing domains on the aaRS enzymes themselves, as well as by stand-alone editing enzymes ([@b0005; @b0460]). These domains and enzymes have the potential to act as targets for drugs, and several aaRS inhibitors are thought to act via inhibition of the editing process ([@b0415; @b0490]).

In addition to their canonical roles in tRNA aminoacylation, these ancient enzymes have also evolved extra functions, in some cases through the acquisition of novel protein domains ([@b0325; @b0455; @b0175]). In eukaryotes in particular, tRNA synthetases also play roles in non-translation processes including the regulation of transcription, RNA splicing, apoptosis, angiogenesis, immune responses and signalling events. These moonlighting functions may be crucial in some organisms, and some inhibitors that focus specifically on these non protein-translation roles of aaRSs have been explored. Non-canonical roles have been suggested for several parasite tRNA synthetases, and we also review the potential for these enzymes as drug targets below.

4. Existing aaRS inhibitors in parasites {#s0020}
========================================

4.1. Alanyl-tRNA synthetase {#s0025}
---------------------------

Alanyl-tRNA synthetase (AlaRS) has been a focus of extensive research due to the presence of an unusual secondary catalytic site with editing activity ([@b0170; @b0465]). Glycine and serine are common misacylations of tRNA^Ala^, and AlaRS enzymes can edit these products of misacylation to ensure they do not accumulate to toxic levels. Mice with defects in tRNA^Ala^ editing have a neurodegeneration phenotype, reinforcing the importance of editing activity ([@b0320]). An AlaX domain found on additional proteins is also involved in the elimination of mischarged tRNA^Ala^ and an AlaX domain has been reported in *Plasmodium*, fused to another tRNA synthetase; *Pf*TrpRS ([@b0260]). AlaRS has also been characterised in *Plasmodium* parasites---only one version of this enzyme is encoded by the *Plasmodium* genome, despite apparent requirements for cytosolic organellar translation. As with the *Pf*GlyRS and *Pf*ThrRS, this enzyme is post-translationally targeted to both the *Plasmodium falciparun* cytosol and the apicoplast, possibly by production of alternatively initiated proteins ([@b0250; @b0215]). [@b0250] screened several putative inhibitors of the *Pf*AlaRS based on *in silico* docking against structural homology models. One of these, 4-{2-nitro-1-propenyl}-1,2-benzenediol ([Table 1](#t0010){ref-type="table"}), inhibited parasite growth at low micromolar inhibition, and produced only limited mammalian cytotoxicity at similar concentrations ([@b0250]). Although it is not yet known if these compounds inhibit the parasite *Pf*AlaRS, the dependence of cytosolic and apicoplast translation on this dual targeted enzyme makes it a conceptually attractive target.

4.2. Asparaginyl-tRNA synthetase {#s0030}
--------------------------------

The cytoplasmic asparaginyl-tRNA synthetase (AsnRS) has been a long-standing drug target in *Brugia malayi*, a nematode that is one of the causative agents of lymphatic filariasis. This enzyme is very highly expressed compared to other *Brugia* aaRSs, and, like other aaRSs mentioned above, appears to have developed non-protein-translation functions in addition to its canonical role. In *Brugia*, the AsnRS is an immunodominant antigen in human infections ([@b0290]) additionally this enzyme catalyses the production of diadenosine triphosphate ([@b0295]) and exhibits immunomodulatory functions associated with inflammation during host infection ([@b0395; @b0300; @b0305]). Because of these apparently key roles, several drug discovery (and diagnostic) projects have focused on this *B. malayi* enzyme.

Two distinct strategies have been employed to find inhibitors of *the B. malayi* enzyme; *in silico* docking and high throughput screening. In the first approach, compounds from publicly available collections were docked against the *B. malayi* AsnRS (*Bm*AsnRS). From this docking, 45 compounds were tested for their inhibition of the *Bm*AsnRS, as assayed by a modified malachite green assay, which provides a readout for the first step in aminoacylation reaction. Of the compounds screened, a handful inhibited AsnRS aminoacylation at mid-micromolar IC~50~s ([Table 1](#t0010){ref-type="table"}) ([@b0485]). Subsequent publication of a more detailed structure for the *Brugia* AsnRS in complex with a substrate analogue that acts as a competitive inhibitor ([@b0080]) may provide additional information to refine future docking experiments or to rationally improve existing inhibitors.

A second approach makes use of an assay that focuses on AsnRS's capacity to recognise and edit misacylation prior to transfer. This pre-transfer editing assay initially identified compounds that promoted the editing activity of *Bm*AsnRS, as well as allowing screening of inhibitors that blocked the *Bm*AsnRS ([Table 1](#t0010){ref-type="table"}) ([@b0100]). The assay was then used to experimentally screen for inhibitors of *Bm*AsnRS among tens of thousands of extracts from diverse microbial strains. Further purification and fractionation of these extracts has led to the discovery of two different compound classes---the Tirandamycins ([@b0535]) and the WS9326A derivatives ([@b0540]) (see [Table 1](#t0010){ref-type="table"})---that each inhibit *Bm*AsnRS aminoacylation and kill adult *B. malayi*. Both classes appear to show some selectivity for *Brugia* compared to human AsnRS. Further optimisation and validation of these inhibitors is reportedly underway ([@b0535; @b0410]).

4.3. Isoleucyl-tRNA synthetase {#s0035}
------------------------------

The protist parasite, *Trypanosoma brucei* is the causative agent of human African trypanosomiasis. There is an urgent need for new, more effective, non-toxic, and cheap antitrypanosomal drugs ([@b0125]). Recent research validates the *Trypanosoma brucei* isoleucyl-tRNA synthetase (IleRS) as a potential drug target, with *ex vivo* and *in vivo* RNAi knockdowns showing IleRS to be essential for *Trypanosoma brucei* growth ([@b0070]). Cestari and Stuart screened 20 compounds from the National Cancer Institute database that were structurally similar to Ile-AMP (the reaction intermediate) for killing of *T. brucei* bloodstream forms. Several active compounds from this screen, including NSC70442 specifically inhibited activity of recombinant *T. brucei* isoleucyl-tRNA sythetase (IleRS) and have good selectivity against mammalian cell lines ([Table 1](#t0010){ref-type="table"}). Furthermore, a transgenic *T. brucei* line that overexpressed IleRS showed reduced sensitivity to NSC70442 and other Ile-AMP analogues, supporting IleRS as the target of these inhibitors. NSC70442 cured in *T. brucei*-infected mice at low mammalian toxicity ([@b0070]). There is also evidence that compounds from this chemical class are able to cross the blood brain barrier ([@b0070]), a very important characteristic for antitrypanosomal drugs that can treat stage 2 trypanosomiasis ([@b0425])

The most widely-used drug that inhibits aminoacyl-tRNA synthetases targets IleRS. Mupirocin (also known as pseudomonic acid, and marketed as Bactroban®), is used for the topical treatment of *Staphylococcus aureus*. Crystal structures of mupirocin-bound IleRS indicate that mupirocin inhibits bacterial IleRS by blocking the binding of the Ile-AMP intermediate ([@b0360]). Mupirocin has now been shown to inhibit blood-stage *P. falciparum* growth in the nanomolar range ([Table 1](#t0010){ref-type="table"}) ([@b0205]). Mupirocin resistant *Plasmodium* parasites have mutations in the apicoplast-located IleRS, indicating that the bacterial type apicoplast IleRS is the target of mupirocin ([@b0205]). This is supported by specific defects in apicoplast morphology and segregation upon mupirocin, and in the "delayed-death" type mupirocin killing of *ex vivo* cultured parasites ([@b0215]), which is characteristic of inhibitors blocking apicoplast maintenance. Mupirocin failed to protect mice from a *Plasmodium berghei* infection, a likely result of the compound's well known *in vivo* instability and its high binding to serum ([@b0065]). Mupirocin itself is therefore very unlikely to serve as a good lead for antiparasitic drug development, but does validate the apicoplast IleRS as a target for specific antimalarial drug research. Istvan and colleagues ([@b0205]) also showed that the *Plasmodium* cytosolic IleRS was inhibited by the isoleucine analogue thiaisoleucine ([Table 1](#t0010){ref-type="table"}), which rapidly killed *ex vivo* cultured parasites. Thiaisoleucine also inhibits mammalian IleRS but its inhibition of *Plasmodium* growth supports the *Plasmodium* cytosolic IleRS enzyme as a potential drug target. Another inhibitor of eukaryotic IleRSs, the cyclic beta amino acid, icofungipen, shows good activity against pathogenic fungi, and has been through phase II human trials ([@b0180]). We are unaware of any tests on the activity of icofungipen in any parasite.

4.4. Leucyl-tRNA synthetase {#s0040}
---------------------------

LeuRS is a proofreading aaRS that is inhibited by 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690) by trapping tRNA^Leu^ in the editing site ([@b0415]). AN2690 has potent antifungal activity, and was reported to be undergoing clinical trials ([@b0440]). Inspired by this success story, inhibitors based on the benzoxaborole core---that contains a boronic acid and forms an adduct with the tRNA---were explored as LeuRS inhibitors for *T. brucei*. For this purpose, a homology model of the *T. brucei* CP1 (editing) domain based on the solved *Candida albicans* LeuRS was used to design a series of benzoxaborole compounds ([@b0115]). Structure--activity relationship was studied, and the best of the compounds ([Table 1](#t0010){ref-type="table"}) inhibited *Tb*LeuRS aminoacylation and *T. brucei ex vivo* growth at low micromolar IC~50~s, with low mammalian cell toxicity ([@b0115]). A subsequent *Tb*LeuRS study ([@b0550]), used a homology model based on the solved *Pyrococcus horikoshii* LeuRS structure ([@b0135]) and instead targeted the enzyme's synthetic site. This study performed *in silico* screening with the SPECS chemical library, and tested a range of compounds with a 2-pyrrolinone scaffold against an *in vitro Tb*LeuRS aminoacylation assay. Though a diverse group of analogues showed some structure--activity relationship, inhibition occurred only at rather high concentrations, with the most potent compounds showing IC~50~s between ∼30 and 100 μM ([Table 1](#t0010){ref-type="table"}) ([@b0550]).

More recently, a new class of *T. brucei* LeuRS inhibitors, N-(4-sulfamoylphenyl)thioureas, which targets the synthetic catalytic site, has been discovered through the screening and modification of a small, targeted library of putative aaRS inhibitors ([@b0545]). This class of inhibitors are designed to inhibit by mimicking the intermediate product, aminoacyl-AMP. To further improve upon the activities of the compounds, *Tb*LeuRS was used to dock inhibitors and guide synthesis of derivatives. The best compound, 59, showed an IC~50~ of 1.1 μM and is predicted to form four hydrogen bonds and favourable hydrophobic interactions with the synthetic enzyme pocket. These compounds exhibited moderate selectivity (4.5--7.3 fold) compared to human cytoplasmic LeuRS, but none of the compounds optimised for inhibition of the synthetic site inhibited growth of *T. brucei* in culture at 100 μM ([Table 1](#t0010){ref-type="table"}). Experiments using caco-2 cell permeability assays indicated that these compounds have poor permeability and may explain the poor inhibition seen in the *ex vivo* bioassays. This new inhibitor class shows early promise as *Tb*LeuRS inhibitors but will require more work to address permeability issues and demonstrate the ability to kill parasites and cure mice infections.

4.5. Lysyl-tRNA synthetase {#s0045}
--------------------------

In a recent comprehensive study, the fungal secondary metabolite cladosporin ([Table 1](#t0010){ref-type="table"}) was shown to inhibit blood and liver proliferation of *P. falciparum* at the nanomolar range ([@b0190]). Studies in fungi showed that heterozygote mutants of LysRS were more sensitive to cladosporin, and fungi with separate point mutations in LysRS were more resistant to cladosporin. *Plasmodium* parasites overexpressing the cytosolic *Pf*LysRS are similarly more resistant to cladosporin. *In silico* docking suggests that cladosporin interacts with the ATP-binding pocket of the LysRS and increasing concentration of ATP *in vivo* significantly reduced inhibition, consistent with this *in silico* prediction. Cladosporin only demonstrated weak inhibition of recombinant human LysRS at high micromolar concentrations, which was postulated to be due to steric hindrance within the ATP-binding pocket ([@b0190]). The crystal structure of the cytoplasmic *Pf*LysRS was subsequently solved, and confirms a structural difference in this region is likely to be the basis for this selectivity ([@b0255]). The structure also describes additional differences that may allow for the design of selective inhibitors that act against the *Plasmodium* but not human LysRS ([@b0255]).

Whilst cladosporin inhibits the *Plasmodium* cytosolic LysRS, Hoen and colleagues ([@b0185]) have pursued the apicoplast *Pf*LysRS isoform as a potential drug target. They constructed a virtual lysyl-adenylate mimic compound library and screened this through *in silico* docking against a homology model of *P. falciparum* apicoplast LysRS. Two of the tested compounds (M-26 and M-37), had potent delayed death inhibition (consistent with apicoplast-specific activity) and inhibited aminoacylation by recombinant apicoplast *Pf*LysRS ([Table 1](#t0010){ref-type="table"}) ([@b0185]). The availability of specific inhibitors for both the cytoplasmic LysRS and the apicoplast LysRS provides ideal tools for studying the relative importance of organellar and cytosolic tRNA synthetases as well as providing promising drug leads. Cladosporin itself possesses poor oral bioavailability and seems therefore to be a poor drug candidate itself ([@b0190]), but may serve as a chemical starting point for other *Pf*LysRS inhibitors.

4.6. Methionyl-tRNA synthetase {#s0050}
------------------------------

One series of compounds that has been investigated as antitrypanosomal agents was inspired by the success of the bacterial MetRS diaryl diamines inhibitors ([Table 1](#t0010){ref-type="table"}) ([@b0090]). These bacterial inhibitors are highly selective for bacterial versus mammalian enzymes. Some of these compounds do inhibit recombinant human mitochondrial MetRS, however no cytotoxicity of mammalian cell cultures is apparent ([@b0160]). Homology models based on several MetRS structures were used to guide synthesis of related *T. brucei* MetRS inhibitors ([Table 1](#t0010){ref-type="table"}), and these were tested for binding to *Tb*MetRS ([@b0445]). Inhibition of aminoacylation activity was assayed at 50 nM and the most interesting of compounds showed \>95% inhibition of activity at this concentration. Compounds were also screened using *ex vivo* cultures of *T. brucei* (and *Trypanosoma cruzi*) and the most effective, compound 1, had an EC50 of 4 nM and low toxicity for mammalian cells. Compound 1 was delivered at 25 mg/kg/day for 3 days using subcutaneous osmotic minipump to circumvent issues with bioavailability, and showed initial suppression of parasitaemia but mice later succumbed to disease ([@b0445]). Partial knockdown of the *T. brucei* MetRS through RNAi produced a severe growth defect, confirming the importance of this enzyme ([@b0445]).

Two subsequent studies characterised structures of the *Leishmania* MetRS ([@b0315]) and the *Tb*MetRS ([@b0275]) bound to substrates, Met, MetAMP and, in the case of the *Tb*MetRS, inhibitors. This study revealed extensive conformational rearrangement by the *Tb*MetRS structure upon inhibitor binding, suggesting conformation selection as the basis for binding ([@b0275]). Inspection of the structures showed extensive rearrangement of the conformations occurred with introduction of inhibitors---with the compound occupying a pocket that was not present with substrates Met or MetAMP---called the auxillary pocket. The crystal structure of ligand-free *Tb*MetRS1 is very similar to the inhibitor-bound conformation of *Tb*MetRS and supports the idea that conformational selection is the likely model for binding of inhibitors to *Tb*MetRS ([@b0275]). The *Lm*MetRS structure additionally revealed several differences from its human homologs near the active site that might be exploited with inhibitors that could specifically target the parasite enzyme ([@b0315]).

To improve upon the earlier MetRS inhibitors that exhibited poor PK profiles and poor bioavailability ([@b0225; @b0230]), the authors made a follow up compound series ([Table 1](#t0010){ref-type="table"}) ([@b0450]). Guided by structures of inhibitor-bound MetRS, it was rationalised that a urea-based scaffold would increase bioavailability. The enzymes were screened using a thermal shift binding assay then used in *in vitro* aminoacylation assays to test for inhibition of *Tb*MetRS and *Hs*MitoMetRS. Compounds had similar IC~50~ and selectivity to the original series and improved pharmacokinetic characteristics, but unfortunately the oral bioavailability remained poor. Nonetheless these authors have demonstrated the importance of this enzyme for parasite growth, as well as the capacity to design specific inhibitors against trypanosomatid MetRS, and this remains a highly promising target.

4.7. Prolyl-tRNA synthetase {#s0055}
---------------------------

One long-used traditional antiparasitic agent, febrifugine, has recently been revealed to inhibit prolyl tRNA synthetase. This quinazolinone alkaloid is a constituent of the Chinese herbal medicine, Chángsān (*Dichroa febrifuga*). Despite excellent antiparasitic activity, its strong liver toxicity and gastrointestinal side effects have limited the use of febrifugine as a widespread therapeutic. Febrifugine analogues have been synthesised with a reduced capacity to form toxic intermediates and have demonstrated potent inhibition of *P. falciparum* isolates in *ex vivo* culture, *P. berghei in vivo* infection and impressive cure rates in an *in vivo* Aotus monkey model ([@b0560; @b0565]). One of these analogues, the synthetic halogenated derivative halofuginone ([Table 1](#t0010){ref-type="table"}), potently inhibits cultured erythrocytic and liver stage *Plasmodium falciparum* ([@b0270; @b0110; @b0245]). Halofuginone has been a US FDA (Food and Drug Administration) approved drug for apicomplexan parasite (coccidia) infections of chickens and turkeys since the 1980s and is currently involved in both Stage I and Stage II clinical trials for use against proliferative diseases that include carcinoma, advanced solid tumours and AIDs related malignancies ([@b0130; @b0120; @b0105; @b0285]).

Recent papers have demonstrated that halofuginone and other febrifugines act through inhibition of ProRS. In an elegant study, [@b0245] demonstrated first that halofuginone (which was known to activate the amino acid starvation response) inhibited an *in vitro* translation assay, and translation was restored only by addition of excess proline. Halofuginone also bound to and inhibited recombinant human ProRS. Addition of excess proline also reduced the sensitivity of *P. falciparum* parasites to halofuginone ([@b0245]). A subsequent study showed that halofuginone specifically blocks the formation of the Pro-AMP adenylate complex ([@b0555]). Interestingly, the inhibition is reliant on the presence of ATP to allow high affinity binding of halofuginone to ProRS. ATP directly assists the orientation of halofuginone to enable one end to occupy the proline binding site and consequently, to competitively block activation of this amino acid, whilst the other end simultaneously mimics the 3′ end of the tRNA molecule. This ATP-dependent binding of halofuginone to ProRS has also been modelled with the *P. falciparum* ProRS, which is predicted to recapitulate these dual site enzyme inhibition interactions ([@b0555]). The apparent efficacy of febrifugines as antimalarial agents, despite their obvious inhibition of human ProRS and proliferating human cells serves as a reminder that drug selectivity for an acute parasitic infection need not necessarily rely on molecular specificity.

4.8. Threonyl-tRNA synthetase {#s0060}
-----------------------------

Borrelidin, first isolated from *Streptomyces spp.*, acts as a non-competitive, selective inhibitor that binds to a unique hydrophobic cluster near the active site of some bacterial and eukaryotic ThrRS enzymes ([@b0365; @b0430; @b0140]). Borrelidin is an inhibitor of yeast cyclin-dependent kinase ([@b0495]) and an activator of pro-apoptotic mediators in endothelial cells ([@b0240]). Several investigations on the effect of borrelidin on *Plasmodium* shine light on its presumed target *Pf*ThrRS ([Table 1](#t0010){ref-type="table"}). Borrelidin potently inhibits parasite proliferation in culture, with an immediate effect on the first asexual erythrocytic life-cycle after treatment, typical of cytosolic inhibition. This inhibition is unlike the delayed-death seen for apicoplast inhibitors ([@b0200; @b0215; @b0025]) and borrelidin does not appear to inhibit organellar division ([@b0215]). *Plasmodium* possesses only one *Pf*ThrRS, a dual-targeted enzyme, which is trafficked to the apicoplast and cytosol ([@b0250; @b0215]). The immediate inhibition seen with Borrelidin is consistent with the requirement of this PfThrRS for cytosolic translation. Although the exact molecular mechanism responsible for the antimalarial effect of borrelidin remains unclear, raised concentrations of [l]{.smallcaps}-Threonine in culture reduce parasite sensitivity, thus implicating threonine utilisation and *Pf*ThrRS as likely targets of borrelidin ([@b0200]).

In addition to its *ex vivo* use, borrelidin has been shown to cure mice of rodent malaria infections ([@b0380; @b0025]), with one report of borrelidin-cured mice then acquiring protection from subsequent challenge by *Plasmodium yoelii* ([@b0025]). Although, borrelidin displays some mammalian cytotoxicity, there are efforts to synthesise borrelidin analogues with decreased toxicity ([@b0515; @b0480]). More recently, [@b0480] generated a borrelidin-like series ([Table 1](#t0010){ref-type="table"}) that reduced the cytotoxicity whilst simultaneously increasing the antimalarial activity, an important step to further progress the development of borrelidin as a future antimalarial drug.

[@b0250] have also investigated novel inhibitors of the *Pf*ThrRS predicted by *in silico* docking of small molecule compound libraries against homology models of the *Pf*ThrRS. The best of these compounds showed only moderate inhibition (IC~50~ from ∼75 to 150 μM) of *ex vivo P. falciparum* growth ([Table 1](#t0010){ref-type="table"}) ([@b0250]).

4.9. Tryptophanyl-tRNA synthetase {#s0065}
---------------------------------

Considerable divergence in sequence and structure of TrpRSs has previously been described across the three domains of life. This has attracted some interest for TrpRS as a drug target, including in parasites. In trypanosomatid parasites this divergence is compounded by the requirement for an additional TrpRS that charges a non-canonical UGA-recognising tRNA^Trp^ required in the parasite's mitochondria. This tRNA is encoded by the same gene as that used for cytosolic translation, but the version used in the mitochondria is first chemically altered through thiol modification and C to U nucleotide editing at the first position of the anticodon ([@b0010]). *T. brucei* encodes two TrpRS enzymes -- one that recognises only the canonical tRNA in the cytosol, plus a second that recognises the altered tRNA in the mitochondrion ([@b0075]). This later *Tb*TrpRS is lineage specific, and presents opportunities for selective inhibition. A similar scenario may exist in the apicoplast of apicomplexan parasites, where the UGA in the apicoplast genome also appears to be partially decoded as tryptophan rather than a stop codon ([@b0520]).

Structural analysis of TrpRS enzymes from various parasites also appears to offer opportunities for selective drug development. Analysis of the crystal structure of TrpRS from *Giardia lamblia* revealed a 16-residue α-helix instead of the hydrophobic ß-hairpin that stabilises the bond between tryptophan and the enzyme ([@b0020]). The *Toxoplasma* and *Trichomonas* sequences also diverge from the human sequence in this area ([@b0020]). These are important sub-domains of the human enzyme, so these marked differences may provide a means of selectively inhibiting the *parasite* homologues. Additional structures for the *T. brucei* cytosolic TrpRS ([@b0350]), the *Cryptosporidium parvum* TrpRS ([@b0350]), and the *P. falciparum* TrpRS ([@b0260; @b0280]) also reveal some additional parasite specific sub-domains or structural differences that might be exploited for drug design purposes. A structure has also been solved for a divergent member of three identified *Entamoeba histolytica* TrpRS homologues, but this enzyme lacks Trp binding and is unlikely to charge tRNA^Trp^ ([@b0350]).

Although no inhibitors have thus far been reported for parasite TrpRSs, several chemical starting points exist for exploration; bacterial TrpRS are inhibited by natural products and tryptophan analogues such as indolmycin ([@b0405; @b0235]) and chuangxinmycin ([@b0055]).

4.10. Tyrosyl-tRNA synthetase {#s0070}
-----------------------------

To our knowledge tyrosyl-tRNA synthetases (TyrRS) have yet to be experimentally investigated as targets for drug development in parasites. However, previous studies have identified inhibitors active against bacterial TyrRS including the naturally derived SB-219383 ([@b0040; @b0470; @b0165]) and several synthetic compounds ([@b0220; @b0525; @b0530; @b0510]). The few parasite-specific studies on TyrRS focused on the structural aspects of the enzyme. Bhatt and colleagues ([@b0045]), localised the cytosolic *Pf*TyrRS to the parasite cytoplasm and noted the additional presence of *Pf*TyrRS within infected erythrocytes. These authors also detected extracellular activity of *Pf*TyrRS through mimicry of host cytokines to induce host immune system pro-inflammatory responses ([@b0045]). In addition to this intriguing discovery, Bhatt et al. solved the crystal structure of *Pf*TyrRS in complex with tyrosyl-adenylate ([@b0045]). Structural comparisons between the *Plasmodium* and human TyrRS revealed many differences such as the organisation of loop structures and included sequence level differences at 11 residues that contribute to binding of substrate ([@b0045]). The crystal structure of the unusual double-length TyrRS orthologue from *Leishmania major* suggest a pseudo-dimer that is formed by asymmetric domains ([@b0310]) that also differs from the host TyrRS. Taken together these differences could potentially be exploited for design of structure-based inhibitors of parasite TyrRSs.

5. Concluding remarks {#s0075}
=====================

As evident in the list of targets above, much of the research on parasite aminoacyl-tRNA synthetases has taken place over the course of the last decade. Building on earlier studies using classical biochemistry, and a small initial number of chemical starting points, the research community is now using a myraid of technologies to investigate aaRSs and has built up an array of inhibitors that represents diverse chemical space. An encouraging development is the recent discovery of new chemicals that inhibit aaRS in eukaryotic parasites including *Brugia*, *Trypanosoma* and *Plasmodium* parasites ([Table 1](#t0010){ref-type="table"}). Detailed structural research has shed important light on the structural basis for aminoacylation, and provides us with insights into the number of ways in which these enzymes can be chemically inhibited. *In silico* docking, rational design of compounds to fit into active sites, as well as high throughput screening have all resulted in the identification of compounds that potently inhibit aaRSs. Several combinatorial and medicinal chemistry programs have modified these starting compounds to develop compounds with acceptable pharmaceutical properties, and there are promising animal-model data for aaRS inhibitors for several parasites. Future investigations will need to consider whether these can genuinely be developed as drug like compounds, and if so, whether this can be achieved cheaply -- a prime consideration for neglected parasitic diseases.

Advances across a number of systems biology platforms are accelerating the ability to make connections between inhibitors and molecular targets in parasites, and to subsequently validate these targets. Identifying resistance mutations that shed light on modes of action has been a long standing means of interrogating aaRS inhibitors. Alongside the current availability and reduced cost of next-generation sequencing technologies now means that target identification has become feasible and affordable for the larger eukaryotic parasite genomes. A number of resistance mapping studies for aaRS inhibitors in *Plasmodium* set a standard for future investigations in this genre ([@b0205; @b0190]).

Two concerns, selectivity and resistance, will remain major challenges for the development of antiparasitic aaRS inhibitors. Despite these parasites being only very distantly related to each other, and cause very different diseases, they share the chemotherapeutic challenge of finding drugs that select between one eukaryote and another (humans). Selectivity is a major issue because the human genome encodes for 36 aminoacyl-tRNA synthetase, (16 cytoplasmic, 17 mitochondrial, 3 dual-targeted) (see review by [@b0015]) that have eukaryotic and bacterial origins (mitochondria). Avoiding inhibition of the most conserved homologs is a challenge in aaRS inhibition to avoid potential cytotoxicity. Strategies to circumvent host toxicity include exploitation of organellar, bacterial-type aaRSs where the human homologue is divergent (such as the *Leishmania* AsnRS with a bacterial origin ([@b0155])) or exploitation of parasite-specific modifications ([@b0050]). It should also be kept in mind that for the protist parasites at least, they are separated by a billion years of evolution from their mammalian hosts, so molecular divergence abounds. In all of these cases, structural information is often key to identifying exploitable differences between host and parasite ([@b0060; @b0310]). It is noteworthy that it is sometimes possible to design aaRS inhibitors with good selectivity even where few differences exist in active site residues between parasite and host ([@b0445]).

Resistance to antiparasitic drugs is a major concern. Eventual resistance to aaRS inhibitors is inevitable, and can only be hoped to be delayed, but this unfortunate outcome is often overlooked in the preclinical stages of drug discovery where the focus is on the optimisation of efficacy, cytotoxicity and pharmacokinetic properties. Since mupirocin, the IleRS inhibitor, was first introduced for clinical use, resistance has developed and in some cases results in mupirocin treatment failure against *S. aureus* ([@b0385]). Parasite drug resistance to aaRS inhibitors has been used in studies characterising aaRS inhibitors in *Plasmodium* ([@b0205]) and *Trypanosoma* ([@b0400]). These studies are helpful not only in informing mode of action but also useful in the prediction of development and extent of parasite drug resistance. They enable discussion of relative fitness and ultimately facilitate the design of inhibitors to which resistance is not so easily generated.
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![Schematic representation of an aminoacyl-tRNA synthetase. Various aaRS domains are illustrated: the editing domain (red); catalytic domain (cyan); anticodon-binding domain (indigo); and parasite-specific domains (purple). Possible sites of interaction between aaRS and compound (with existing examples) are indicated by numbers: editing site (1); active site (2); allosteric sites (3); parasite-specific domains (4); and anticodon-binding site (5). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr1){#f0005}
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Representative inhibitors of aminoacyl tRNA synthetases in parasites and other infectious agents. The names of the structures shown are indicated in bold text. Structures are derived from PubChem, Chemspider or redrawn from original papers.
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^a^ Predicted site of action. ([@b0250; @b0485; @b0100; @b0535; @b0540; @b0205; @b0335; @b0070; @b0115; @b0550; @b0590; @b0190; @b0185; @b0445; @b0450; @b0085; @b0090; @b0245; @b0555; @b0380; @b0480].)

[^1]: Charisse Flerida is a double name.
